Niraparib and Dostarlimab in HRD Solid Tumors

计划入组 30 人 · 首次发布于 2021 年 7 月 30 日

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

计划入组 7 人 · 首次发布于 2023 年 10 月 3 日

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

计划入组 35 人 · 首次发布于 2021 年 4 月 1 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

BioLine Rx

Israel

IDEAYA Biosciences Announces Strategic Updates and 2025 Corporate Guidance

Huons Wins Three State Drug Development Grants to Advance mRNA Eye Drop, ADC and Peptide Cancer Drug

Eisbach Bio Relocates to Houston with $4.75M CPRIT Grant to Advance EIS-12656 Trial in HRD Tumors